The "Other" signaling of trastuzumab: Antibodies are immunocompetent drugs

被引：17
作者：
Gianni, Luca [1 ]
机构：
[1] Fdn Ist Nazl Tumori, Div Med Oncol Clin Pharmacol & New Drug Dev, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 11期
关键词：
D O I：
10.1200/JCO.2007.15.7404
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1778 / 1780
页数：3
相关论文
共 21 条
[1]  
[Anonymous], 29 ANN SAN ANT BREAS
[2]  
[Anonymous], J CLIN ONCOL S
[3]   Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].
Arnould, L ;
Gelly, M ;
Penault-Llorca, F ;
Benoit, L ;
Bonnetain, F ;
Migeon, C ;
Cabaret, V ;
Fermeaux, V ;
Bertheau, P ;
Garnier, J ;
Jeannin, JF ;
Coudert, B .
BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267
[4]   Cellular immunity in breast cancer patients completing taxane treatment [J].
Carson, WE ;
Shapiro, CL ;
Crespin, TR ;
Thornton, LM ;
Andersen, BL .
CLINICAL CANCER RESEARCH, 2004, 10 (10) :3401-3409
[5]   Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129
[6]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[7]   Fc receptors are required in passive and active immunity to melanoma [J].
Clynes, R ;
Takechi, Y ;
Moroi, Y ;
Houghton, A ;
Ravetch, JV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :652-656
[8]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[9]   Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex [J].
Franklin, MC ;
Carey, KD ;
Vajdos, FF ;
Leahy, DJ ;
de Vos, AM ;
Sliwkowski, MX .
CANCER CELL, 2004, 5 (04) :317-328
[10]   Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 [J].
Gennari, R ;
Menard, S ;
Fagnoni, F ;
Ponchio, L ;
Scelsi, M ;
Tagliabue, E ;
Castiglioni, F ;
Villani, L ;
Magalotti, C ;
Gibelli, N ;
Oliviero, B ;
Ballardini, B ;
Da Prada, G ;
Zambelli, A ;
Costa, A .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5650-5655
123